Does pharmaceutical advertising affect journal publication about dietary supplements?

Dieses Thema enthält 0 Antworten und 1 Teilnehmer. Es wurde zuletzt aktualisiert von Markus Markus 01.01.2015 um 12:43.

Ansicht von 1 Beitrag (von insgesamt 1)
  • Autor
    Beiträge
  • #87693 (0)
    Markus
    Markus
    Teilnehmer
    33
    Beiträge: 2674

    Je mehr Pharmaanzeigen in einem wissenschaftlichen Journal erscheinen um so weniger Studien über Supplements ("DS") werden dort veröffentlicht. Und die, die dennoch erscheinen sind mit einem deutlich negativen Conclusio. Alles hochsignifikant (p=0,01) oder anders gesagt: kein Zufall, sondern Kalkül. Knallhartes, Marktwirtschaft eben. Käuflichkeit der Journallie.

    Abstract
    Background

    Advertising affects consumer and prescriber behaviors. The relationship between pharmaceutical advertising and journals‘ publication of articles regarding dietary supplements (DS) is unknown.
    Methods

    We reviewed one year of the issues of 11 major medical journals for advertising and content about DS. Advertising was categorized as pharmaceutical versus other. Articles about DS were included if they discussed vitamins, minerals, herbs or similar products. Articles were classified as major (e.g., clinical trials, cohort studies, editorials and reviews) or other (e.g., case reports, letters, news, and others). Articles‘ conclusions regarding safety and effectiveness were coded as negative (unsafe or ineffective) or other (safe, effective, unstated, unclear or mixed).
    Results

    Journals‘ total pages per issue ranged from 56 to 217 while advertising pages ranged from 4 to 88; pharmaceutical advertisements (pharmads) accounted for 1.5% to 76% of ad pages. Journals with the most pharmads published significantly fewer major articles about DS per issue than journals with the fewest pharmads (P < 0.01). Journals with the most pharmads published no clinical trials or cohort studies about DS. The percentage of major articles concluding that DS were unsafe was 4% in journals with fewest and 67% among those with the most pharmads (P = 0.02). The percentage of articles concluding that DS were ineffective was 50% higher among journals with more than among those with fewer pharmads (P = 0.4).
    Conclusion

    These data are consistent with the hypothesis that increased pharmaceutical advertising is associated with publishing fewer articles about DS and publishing more articles with conclusions that DS are unsafe. Additional research is needed to test alternative hypotheses for these findings in a larger sample of more diverse journals.

    http://www.biomedcentral.com/1472-6882/8/11

Ansicht von 1 Beitrag (von insgesamt 1)

Sei müssen angemeldet sein, um auf dieses Thema antworten zu können. Bitte loggen Sie sich ein.